
Conference Coverage
Latest Content

Invivyd Announces FDA Clearance of IND Application for VYD2311 and Advancement of REVOLUTION Clinical Program

UCF Team Advances Low-Cost Multiplex RNA Test for HIV, HBV, and HCV

Phase 3 Trial Confirms Superior Efficacy of Oral Pritelivir for Refractory HSV in Immunocompromised Patients

Developing the Next Generation of Rifamycins for Non-TB Mycobacteria in a Postantibiotic Era

Higher Acceptability of One Injectable in First Head-to-Head Comparison of Long-Acting PrEP

Shorts







Podcasts
Videos
Contagion Digital Edition







All News

A UK hepatology review found that one-third of adults with chronic hepatitis B were lost to specialist follow-up—highlighting major gaps in patient retention that threaten progress toward WHO’s 2030 viral hepatitis elimination goals.

A 4-week course of glecaprevir/pibrentasvir achieved sustained virologic response in 84% of patients with early hepatitis C infection in the PURGE-C trial, suggesting potential for shorter, more accessible treatment regimens pending further validation.

George Sakoulas, MD, discusses how ceftaroline serves as an effective stewardship-aligned option for community-acquired pneumonia involving gram-positive organisms, particularly in older and high-risk patients, while noting its limitations in gram-negative and health care–associated infections.

Barry Kreiswirth, PhD, discusses how taking an approach similar to that for streptococcal pneumonia can be applied to a potential Klebsiella vaccine.

John Osiecki, PhD, explains how faster, standardized testing can speed detection and strengthen antimicrobial stewardship.

Cefiderocol is noninferior to standard of care empiric treatment of noscomial Gram-negative bloodstream infections in open-label "Game-Changer" trial.

This week, learn about the Center for Discovery and Innovation's research around antivirals, the hepatitis C bill in Congress, how AI is influencing antimicrobial development, and more.

The Center for Discovery and Innovation’s Barry Kreiswirth, PhD, discusses this emerging challenge that is ongoing in both the community and healthcare settings, especially around resistant urinary tract infections and how this type of resistance can grow exponentially across strain and pathogens.

AI predicted mechanism of action for investigational, narrow spectrum antibiotic against pathogens in Crohn's disease and IBD-related conditions.

David Perlin, PhD, chief scientific officer and executive vice president, the Center for Discovery and Innovation (CDI), talks about his team’s work around developing a diagnostic for Candida auris, and what they are working on in terms of developing antifungals.

The company is advancing R327G, a novel synthetic anti-infective for diabetic foot infections, through a phase 3 clinical trial in Indonesia, marking a major step toward the first new anti-infective class approval in over 40 years.

The Center for Discovery and Innovation’s chief scientific officer David Perlin, PhD, discusses the factors for the growing number of cases and the difficulties in developing such treatments.

Through the bipartisan Cure Hepatitis C Act of 2025, legislation seeks to provide nationwide hepatitis C treatment and strengthen public health infrastructure by expanding testing, treatment, and prevention through a subscription-based model.

The center’s chief scientific officer David Perlin, PhD, provides some insights on the evolution of its antiviral program from its foundation in treating COVID-19 to addressing all pan-coronaviruses.

Your liver silently powers and protects your body every day, but untreated hepatitis infections, excessive alcohol, and poor diet can destroy its vital cells, leading to fatigue, cirrhosis, and liver cancer if not prevented through awareness and care.